Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut allergy was not achieved, according to results published in Allergy.“The ...

The FDA has approved the use of dupilumab for treating eosinophilic esophagitis in children aged 1 to 11 years who weigh at least 15 kg, according to a press release. The approval expands the use ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent, Regeneron/Sanofi) for the treatment of eosinophilic esophagitis (EoE) in children aged 1-11 years and weighing ≥ 15 kg ...

She added that dupilumab has the exciting potential to transform the standard of care for many young children living with EoE. "There are, however, factors to consider before switching a child to ...

DUPIXENT® (dupilumab injection) approved in Canada for the treatment of children aged 1 year and older with eosinophilic esophagitis (EoE) Thursday, September 12, 2024 Child Health News.

Patients with AD treated with dupilumab have a lower risk of various infections than those treated with methotrexate or cyclosporine.

Majority of patients in this age group with eosinophilic esophagitis (EoE) receiving Dupixent achieved histologic remission, with improvements sustained up to one year ...

Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis Nov. 06, 2024 1:00 AM ET Sanofi (SNY) , REGN ...

Based on its established safety and efficacy, the investigators conducted a phase 3 clinical trial in 408 children between the ages of 6 and 11 who had uncontrolled moderate-to-severe asthma. Children ...

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Health Canada has issued a Notice of Compliance (NOC) for DUPIXENT® (dupilumab injection) for the treatment of patients aged 1 year and older, weighing at least 15 kg, with eosinophilic ...

Health Canada has issued a Notice of Compliance (NOC) for DUPIXENT® (dupilumab injection) for the treatment of patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis ...